What is transcutaneous spinal cord stimulation?
Transcutaneous spinal cord stimulation (tSCS) delivers electrical stimulation to the spinal cord through surface electrodes placed on the skin over the spine. It represents a non-invasive alternative to epidural spinal cord stimulation, which requires surgical implantation of electrodes directly onto the spinal cord.
The primary therapeutic targets are spinal circuits below the level of injury. By modulating the excitability of these circuits, tSCS aims to enhance voluntary movement, reduce spasticity, and improve autonomic function. The approach is grounded in the principle that spinal networks retain significant capacity for reorganisation even after severe injury, and that appropriate stimulation can help unlock that capacity when combined with active rehabilitation.
Mechanism of action
Stimulation activates posterior root afferents, which in turn modulate the excitability of spinal interneuron networks. This has several downstream effects on spinal circuit function.
The key mechanisms include:
- Restoration of KCC2 membrane expression on motoneurons. Following spinal cord injury, the potassium-chloride cotransporter KCC2 is downregulated, disrupting chloride homeostasis and converting normally inhibitory GABAergic signalling into excitatory activity. This contributes to spasticity and hyperreflexia. Repeated tSCS sessions restore KCC2 expression, normalising the chloride gradient and re-establishing effective inhibition.
- Modulation of H-reflex pathways. tSCS alters the excitability of monosynaptic reflex arcs, contributing to improved motor control and reduced spasticity.
- Enhanced postsynaptic reciprocal Ia inhibition and presynaptic inhibition. These inhibitory mechanisms remain enhanced for a period after stimulation ceases, directly contributing to the observed carryover window.
A critical concept is that tSCS creates a neuroplastic window rather than producing direct motor effects. When delivered concurrently with voluntary motor attempts, the enhanced spinal circuit excitability allows activity-dependent strengthening of synaptic connections to occur. The stimulation primes the spinal cord for learning; the training drives the functional change.
The 2-hour carryover window is well characterised: a single 30-minute session produces measurable improvements in walking performance, postural control, and spasticity that persist for approximately 2 hours. Neurophysiological studies confirm that enhanced reciprocal Ia inhibition and presynaptic inhibition persist during the first 3 to 75 minutes post-stimulation, returning to baseline by 120 to 190 minutes. This directly explains the functional carryover window and informs clinical scheduling.
Clinical evidence
The evidence base for tSCS spans several indications relevant to spinal cord injury rehabilitation.
| Indication | Key Evidence | Status | |-----------|-------------|--------| | Upper limb function (SCI) | Up-LIFT trial: 72% achieved clinically meaningful improvement in arm and hand strength and function | Published | | Walking function (SCI) | Year-long pilot: improvements continued over 120 sessions with no apparent plateau | Published | | Spasticity reduction | Single sessions produce 2 to 24 hour reductions; Modified Ashworth Scale improvements persist at 24 hours | Published | | Cardiovascular autonomic function | Improvements in chronic cervical SCI persisting for several weeks after 6 sessions over 2 weeks | Published |
A consistent finding across studies is the importance of treatment duration. A minimum of 60 sessions appears necessary for sustained functional improvements in chronic spinal cord injury. Post-hoc analyses from a multicentre trial confirmed that improvements required at least 60 tSCS plus activity-based therapy sessions, with larger effect sizes as session counts increased.
Perhaps more striking is the absence of a plateau. A year-long pilot study documented that "slow and gradual improvements in outcome measures continued to be noted over the 120 sessions, which did not seem to plateau at the conclusion of the study." This suggests that extended treatment protocols may continue to yield functional gains well beyond conventional rehabilitation timeframes.
Stimulation parameters
The following table summarises typical stimulation parameters used in current clinical practice and research. It is worth noting that parameter optimisation remains an active area of investigation, and individualisation based on patient response is essential.
| Parameter | Typical Range | |-----------|--------------| | Frequency | 15 to 50 Hz (30 Hz common) | | Pulse width | 1 to 2 ms | | Amplitude | Up to tolerance; higher for motor-complete (AIS B) than incomplete (AIS C-D) injuries | | Session duration | 30 minutes stimulation + 60 to 90 minutes continued training | | Frequency of sessions | 2 to 5 times per week; 3 times per week standard for long protocols |
The dose-response relationship for tSCS is generally linear: more sessions produce greater benefit, with the minimum 60-session threshold as a clinically important benchmark. Higher amplitudes within tolerance produce stronger effects, though tolerability naturally limits the upper boundary. Individuals with AIS B (motor-complete) injuries typically require significantly higher amplitudes than those with AIS C-D (incomplete) injuries to achieve equivalent motor responses.
A hierarchical parameter adjustment framework has been proposed based on data from 77 participants across two large SCI trials: (1) gradually increase current amplitude to achieve motor effects or maximum tolerance, (2) select waveform type based on tolerability, (3) optimise electrode positioning for the target spinal level, and (4) adjust burst frequency based on the application (30 Hz for motor function, 50 Hz for spasticity management).
Carryover effects
The persistence of therapeutic benefits after stimulation ceases follows a tiered pattern that has important implications for treatment scheduling and patient expectations.
Immediate carryover (up to 2 hours). A single 30-minute session produces measurable improvements in motor function and spasticity that persist for approximately 2 hours. Modified Ashworth Scale improvements for muscle tone may persist beyond this, with reductions still measurable at 24 hours. This window is clinically useful: the standard protocol delivers 30 minutes of stimulation concurrent with training, followed by 60 to 90 minutes of continued training without stimulation, capitalising on the carryover period.
Extended carryover (days to weeks). Multi-session protocols produce benefits that persist beyond the immediate window. Cardiovascular autonomic improvements in chronic cervical SCI persisted for several weeks after just six 30-minute sessions over two weeks, though effects had diminished by a 6-week assessment. In a targeted cervical tSCS protocol, participant gains persisted during a 3-week period without stimulation following 16 weeks of continuous weekly treatment.
Long-term neuroplastic persistence (months). The most compelling evidence for sustained structural reorganisation comes from individual case reports. A participant with chronic cervical SCI (C3, 8 months post-injury) underwent approximately 4 to 5 weeks of tSCS combined with physical therapy. Following intervention, the neurological level of injury improved from C3 to C4, and this was sustained for 3 months of follow-up with no additional stimulation or therapy. The participant resumed self-feeding for the first time since injury, with functional improvements persisting throughout follow-up. Animal models provide mechanistic support: rats receiving 18 sessions of tSCS over 6 weeks demonstrated sustained restoration of KCC2 membrane expression on lumbar motoneurons, a structural change that persisted at the 6-week endpoint.
These observations are encouraging, though it is important to note that long-term carryover data remains limited and derives primarily from case reports and small pilot studies. Larger studies with systematic long-term follow-up are needed.
The Stim2Go device
The Stim2Go is a wearable programmable stimulator designed by SensorStim Neurotechnology GmbH in Berlin and manufactured by Pajunk GmbH in Geisingen, Germany. The device features app-based control and uses self-adhesive electrode pads for transcutaneous spinal cord stimulation protocols.
Anatomical Concepts (UK) Limited are the UK dealers for the Stim2Go device, providing clinical support, training, and parameter optimisation for rehabilitation teams implementing tSCS protocols.
Safety and contraindications
Transcutaneous spinal cord stimulation is generally well tolerated across the published literature. Safety data from large-scale trials, including analysis of 77 participants across two major SCI trials, confirm that device-related adverse events are infrequent and not correlated with specific waveforms or stimulation amplitudes.
Common side effects include skin irritation or redness at electrode sites, tingling or prickling sensations (which typically adapt within the first few sessions), and transient discomfort during initial amplitude escalation. These are manageable through parameter adjustment and electrode repositioning.
Careful patient selection is required. Clinician assessment and parameter setting is essential prior to initiating treatment. Individual response varies considerably, and a structured titration period over the first 2 to 3 sessions is recommended, with documented parameter adjustments and functional outcome tracking.
No serious adverse events attributable to tSCS stimulation have been reported in major clinical trials involving hundreds of participants across thousands of sessions. The safety profile has supported application in paediatric populations and in home-based settings following appropriate in-clinic training.